RXi Pharma Licenses Thermo Fisher's RNAi Sequences for Drug Programs

Dec 14, 2007

NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed RNAi sequences from Thermo Fisher Scientific to a number of target genes for use in the development of therapeutic compounds for several common diseases, RXi said today.

Under the agreement, RXi will use RNAi sequences generated by Thermo Fisher Dharmacon’s sequence selection algorithm for its rxRNA compound program, which focuses on developing therapeutics for type 2 diabetes, obesity, neurology, and oncology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Like Sears, But With Cells

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Infertile Mouse No More

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

PGD Growth Spurt

China is embracing preimplantation genetic diagnosis, Nature News reports.

This Week in PLOS

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.

Main menu